Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
5
Teradata Corp
TDC
US OptionsDetailed Quotes
MLTX250516C50000
- 0.20
- -0.38-65.52%
15min DelayClose Apr 24 16:00 ET
0.20High0.20Low
0.20Open0.58Pre Close5 Volume632 Open Interest50.00Strike Price100.00Turnover63.77%IV27.25%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.0768Delta0.0234Gamma197.25Leverage Ratio-0.0203Theta0.0017Rho15.15Eff Leverage0.0139Vega
MoonLake Immunotherapeutics Newsroom
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Good Position To Deliver On Growth Plans
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
MoonLake Obtains $500 Million Facility From Hercules Capital
MoonLake Immunotherapeutics Secures up to $500M in Non-dilutive Financing
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $81
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $80
RBC Capital Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $67
New Analyst Forecast: $MLTX Given $67.0 Price Target
MoonLake Immunotherap Price Target Announced at $67.00/Share by RBC Capital
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
MoonLake Earns New Outperform at RBC Capital Markets on Lead Drug
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
MoonLake Immunotherapeutics Advances Clinical Trials in 2024
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now